NASH
MCID: NNL002
MIFTS: 55

Nonalcoholic Steatohepatitis (NASH)

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 54 74
Non-Alcoholic Steatohepatitis 54 17
Non-Alcoholic Fatty Liver Disease 54
Nash 54

Classifications:



External Ids:

UMLS 74 C3241937

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 54 Nonalcoholic steatohepatitis, or NASH, is a common, often �??silent�?� liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic steatohepatitis, is related to nonalcoholic fatty liver disease and hepatitis. An important gene associated with Nonalcoholic Steatohepatitis is SQSTM1 (Sequestosome 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Ezetimibe and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Non-alcoholic fatty liver disease (NAFLD) is when excess fat builds up in the liver due to causes other... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 nonalcoholic fatty liver disease 32.3 ADIPOQ INS KRT18 LEP PNPLA3
2 hepatitis 31.1 GPT KRT18 SLC17A5 TNF
3 hepatitis c 31.0 GPT KRT18 TNF
4 fatty liver disease 30.9 ADIPOQ CYP2E1 IL6 INS LEP PNPLA3
5 lipid metabolism disorder 30.8 ADIPOQ INS LEP
6 glucose intolerance 30.8 ADIPOQ INS LEP
7 morbid obesity 30.7 ADIPOQ INS LEP
8 cryptogenic cirrhosis 30.7 HFE KRT18
9 gestational diabetes 30.6 ADIPOQ INS LEP
10 hepatitis b 30.6 GPT SLC17A5 TNF
11 infantile liver failure syndrome 1 30.4 GPT SLC17A5
12 lipodystrophy, familial partial, type 2 30.4 INS LEP
13 coronary heart disease 1 30.3 ADIPOQ IL6 INS
14 hyperglycemia 30.2 ADIPOQ INS LEP
15 burns 30.2 INS TNF
16 acanthosis nigricans 30.2 ADIPOQ INS LEP
17 arteries, anomalies of 30.2 ADIPOQ IL6 INS LEP TNF
18 fatty liver disease, nonalcoholic 1 30.0 ADIPOQ GPT INS KRT18 LEP SLC17A5
19 diabetes mellitus, noninsulin-dependent 29.9 ADIPOQ GPT IL6 INS LEP SLC17A5
20 cholangitis 29.9 GPT IL6 TNF
21 arteriosclerosis 29.8 ADIPOQ IL6 INS
22 ischemic heart disease 29.8 IL6 TNF
23 sleep apnea 29.8 ADIPOQ IL6 INS LEP TNF
24 alcoholic liver cirrhosis 29.8 CYP2E1 PNPLA3 SLC17A5
25 chronic kidney failure 29.7 ADIPOQ IL6 INS LEP
26 vascular disease 29.6 ADIPOQ IL6 INS TNF
27 large intestine cancer 29.6 ADIPOQ IL6 INS TNF
28 atherosclerosis susceptibility 29.6 ADIPOQ IL6 INS TNF
29 diabetes mellitus 29.6 ADIPOQ HFE IL6 INS LEP TNF
30 apnea, obstructive sleep 29.5 ADIPOQ IL6 INS LEP TNF
31 liver cirrhosis 29.5 ADIPOQ CYP2E1 GPT HFE KRT18 LEP
32 viral hepatitis 29.4 GPT HFE KRT18 SLC17A5 TNF
33 alcoholic hepatitis 29.3 CYP2E1 GPT IL6 KRT18 SLC17A5 TNF
34 overnutrition 29.0 ADIPOQ IL6 INS LEP TNF
35 body mass index quantitative trait locus 11 28.5 ADIPOQ CYP2E1 GPT IL6 INS LEP
36 liver disease 28.5 ADIPOQ CYP2E1 GPT HFE IL6 INS
37 hepatocellular carcinoma 10.8
38 coronary artery anomaly 10.6
39 hepatitis c virus 10.5
40 heart disease 10.5
41 hemosiderosis 10.4
42 paraquat poisoning 10.4 GPT SLC17A5
43 hypertension, essential 10.4
44 pyridoxine deficiency 10.4 GPT SLC17A5
45 adult dermatomyositis 10.4 GPT TNF
46 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.3 ADIPOQ INS
47 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.3 INS LEP
48 lipodystrophy, familial partial, type 1 10.3 INS LEP
49 opisthorchiasis 10.3 GPT TNF
50 complete generalized lipodystrophy 10.3 INS LEP

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 ADIPOQ CYP2E1 HFE IL6 INS LEP
2 homeostasis/metabolism MP:0005376 10.07 ADIPOQ CYP2E1 HFE IL6 INS LEP
3 growth/size/body region MP:0005378 10.06 ADIPOQ HFE IL6 INS KRT18 LEP
4 cellular MP:0005384 10.03 ADIPOQ HFE IL6 INS LEP SLC17A5
5 adipose tissue MP:0005375 10.02 ADIPOQ IL6 INS LEP PNPLA3 SQSTM1
6 liver/biliary system MP:0005370 10.02 ADIPOQ CYP2E1 HFE IL6 INS KRT18
7 mortality/aging MP:0010768 9.96 ADIPOQ CYP2E1 HFE IL6 INS KRT18
8 nervous system MP:0003631 9.56 ADIPOQ HFE IL6 INS LEP SLC17A5
9 neoplasm MP:0002006 9.55 ADIPOQ CYP2E1 IL6 LEP TNF
10 skeleton MP:0005390 9.23 ADIPOQ GPT HFE IL6 INS LEP

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
2
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
3
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
4
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
5
Ribavirin Approved Phase 4,Not Applicable 36791-04-5 37542
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
7
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
11
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
12
Rifaximin Approved, Investigational Phase 4,Not Applicable 80621-81-4 6436173 46783403
13
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
14
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
15
Empagliflozin Approved Phase 4 864070-44-0
16
Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-02-9 14985
18
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
20 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6829-55-6
21 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
26 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Raltegravir Potassium Phase 4
28 HIV Integrase Inhibitors Phase 4
29 Anti-HIV Agents Phase 4,Phase 3,Phase 2
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Integrase Inhibitors Phase 4
33 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Tocotrienols Phase 4,Phase 3,Phase 2,Not Applicable
35 Tocopherols Phase 4,Phase 3,Phase 2,Not Applicable
36 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
43 Antioxidants Phase 4,Phase 3,Phase 2,Not Applicable
44 Nutrients Phase 4,Phase 3,Phase 2,Not Applicable
45 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
46 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
47 Interferon-alpha Phase 4,Not Applicable
48 interferons Phase 4,Not Applicable
49 Interferon alpha-2 Phase 4,Not Applicable
50 Flax Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 373)
# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
3 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
6 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
7 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
8 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
9 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
10 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
11 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
12 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
13 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Recruiting NCT03198572 Phase 4 Placebo;Berberine
14 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
15 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
16 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
17 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
18 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
19 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
20 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
21 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
22 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
23 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
24 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
25 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
26 Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis Completed NCT00820651 Phase 3
27 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
28 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
29 Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Completed NCT00509418 Phase 3
30 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
31 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
32 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
33 Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
34 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
35 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed NCT02279524 Phase 2, Phase 3 Aramchol
36 The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
37 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
38 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
39 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
40 DHA and Vitamin D in Children With Biopsy-proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
41 Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. Completed NCT01245608 Phase 3 Polypill
42 Development of a Breath Test for Monitoring Patients With Liver Disease Completed NCT00244569 Phase 3 13C-Methacetin
43 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
44 Hydroxytyrosol and Vitamin E in Pediatric NASH Completed NCT02842567 Phase 3 Hydroxytyrosol plus Vitamin E;Placebo
45 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3 Recombinant GH Saizen (Merck-Serono)
46 Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT00655018 Phase 2, Phase 3
47 Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Completed NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
48 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3 Elafibranor;Placebo
49 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
50 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Recruiting NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

42
Liver, Testes, Kidney, Endothelial, Heart, Bone, Spleen

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 2821)
# Title Authors Year
1
Non-alcoholic steatohepatitis aggravates nitric oxide synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rat model. ( 30680827 )
2019
2
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. ( 30908822 )
2019
3
The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. ( 30765939 )
2019
4
Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. ( 30877708 )
2019
5
Letter: Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. ( 30819009 )
2019
6
Response: Letter: Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. ( 30821517 )
2019
7
Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus? ( 30847693 )
2019
8
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. ( 30684076 )
2019
9
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease. ( 30905208 )
2019
10
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. ( 30762163 )
2019
11
Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( 30763050 )
2019
12
Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. ( 30298568 )
2019
13
Chronic intermittent hypoxia accelerates liver fibrosis in rats with combined hypoxia and nonalcoholic steatohepatitis via angiogenesis rather than endoplasmic reticulum stress. ( 30668625 )
2019
14
The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. ( 30593409 )
2019
15
Validation of Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis in Patients with Biopsy-Proven Non-alcoholic Steatohepatitis. ( 30639779 )
2019
16
Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis? ( 30454829 )
2019
17
HSPA12A Is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-Mediated M1 Macrophage Polarization. ( 30455376 )
2019
18
Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis. ( 30539788 )
2019
19
STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. ( 30561388 )
2019
20
Blackcurrant (Ribes nigrum) Prevents Obesity-Induced Nonalcoholic Steatohepatitis in Mice. ( 30569636 )
2019
21
High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. ( 30608932 )
2019
22
Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. ( 30609187 )
2019
23
Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. ( 30611667 )
2019
24
A cut-off value of shear wave speed to distinguish nonalcoholic steatohepatitis candidates. ( 30633176 )
2019
25
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. ( 30653691 )
2019
26
Predicting outcomes of liver transplantation in patients with NASH: pre-transplant renal function is key. ( 30657244 )
2019
27
Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. ( 30658094 )
2019
28
Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic 18F-FDG PET. ( 30673340 )
2019
29
Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. ( 30700851 )
2019
30
FBXW5 mediates the ubiquitination of ASK1 and exacerbates nonalcoholic steatohepatitis. ( 30703849 )
2019
31
Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. ( 30705600 )
2019
32
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. ( 30707282 )
2019
33
Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. ( 30720095 )
2019
34
Novel Interplay Between Sonic Hedgehog and Transforming Growth Factor-β1 in Human Nonalcoholic Steatohepatitis. ( 30720468 )
2019
35
RLA8 - A new and highly effective quadruple PPARs-α/γ/δ and GPR40 agonist to reverse nonalcoholic steatohepatitis and fibrosis. ( 30745416 )
2019
36
Review article: consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. ( 30761572 )
2019
37
An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. ( 30766962 )
2019
38
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. ( 30772256 )
2019
39
Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis. ( 30779990 )
2019
40
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. ( 30791778 )
2019
41
Considering Bariatric Surgery in Patients With Nonalcoholic Steatohepatitis-Worth the Risk. ( 30794294 )
2019
42
Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. ( 30794300 )
2019
43
Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. ( 30794826 )
2019
44
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis. ( 30805949 )
2019
45
Antifibrotic Effects of 1,25(OH)2D3 on Nonalcoholic Steatohepatitis in Female Mice. ( 30825110 )
2019
46
Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. ( 30830270 )
2019
47
Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. ( 30841442 )
2019
48
Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes. ( 30848827 )
2019
49
A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. ( 30855276 )
2019
50
Resolving inflammation in nonalcoholic steatohepatitis. ( 30855277 )
2019

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

Pathways related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 ADIPOQ CYP2E1 IL6 INS LEP TNF
2
Show member pathways
12.23 ADIPOQ IL6 INS LEP TNF
3
Show member pathways
11.99 IL6 SQSTM1 TNF
4 11.69 IL6 LEP TNF
5
Show member pathways
11.62 IL6 INS TNF
6 11.57 IL6 INS SQSTM1
7
Show member pathways
11.48 ADIPOQ INS TNF
8 11.27 ADIPOQ LEP TNF
9 11.22 ADIPOQ IL6 INS LEP PNPLA3 TNF
10 10.99 IL6 TNF
11 10.89 ADIPOQ LEP
12 10.76 IL6 TNF
13 10.66 GPT INS
14 10.6 ADIPOQ IL6 LEP TNF

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ADIPOQ GPT HFE IL6 INS LEP

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 HFE IL6 INS TNF
2 positive regulation of protein phosphorylation GO:0001934 9.83 ADIPOQ SQSTM1 TNF
3 positive regulation of protein kinase B signaling GO:0051897 9.82 INS LEP TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 IL6 INS TNF
5 positive regulation of MAPK cascade GO:0043410 9.79 IL6 INS LEP
6 response to ethanol GO:0045471 9.71 ADIPOQ CYP2E1 LEP
7 glucose homeostasis GO:0042593 9.7 ADIPOQ INS LEP
8 response to bacterium GO:0009617 9.69 ADIPOQ CYP2E1 SLC17A5
9 positive regulation of cytokine production GO:0001819 9.67 LEP TNF
10 positive regulation of cytokine secretion GO:0050715 9.66 INS TNF
11 positive regulation of interleukin-8 production GO:0032757 9.66 ADIPOQ TNF
12 positive regulation of JAK-STAT cascade GO:0046427 9.65 IL6 LEP
13 negative regulation of neurogenesis GO:0050768 9.65 IL6 TNF
14 regulation of signaling receptor activity GO:0010469 9.65 ADIPOQ IL6 INS LEP TNF
15 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
16 leukocyte tethering or rolling GO:0050901 9.62 LEP TNF
17 positive regulation of long-term synaptic potentiation GO:1900273 9.62 INS SQSTM1
18 negative regulation of lipid catabolic process GO:0050995 9.61 INS TNF
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 INS LEP TNF
20 positive regulation of cellular protein metabolic process GO:0032270 9.6 ADIPOQ INS
21 positive regulation of glial cell proliferation GO:0060252 9.59 IL6 TNF
22 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 INS LEP
23 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.58 SQSTM1 TNF
24 response to glucocorticoid GO:0051384 9.58 ADIPOQ IL6 TNF
25 negative regulation of gluconeogenesis GO:0045721 9.57 ADIPOQ INS
26 negative regulation of glucose import GO:0046325 9.56 LEP TNF
27 negative regulation of growth of symbiont in host GO:0044130 9.55 SQSTM1 TNF
28 negative regulation of fat cell differentiation GO:0045599 9.5 ADIPOQ IL6 TNF
29 regulation of protein secretion GO:0050708 9.49 INS TNF
30 positive regulation of peptide hormone secretion GO:0090277 9.48 HFE INS
31 negative regulation of receptor binding GO:1900121 9.46 ADIPOQ HFE
32 positive regulation of neuroinflammatory response GO:0150078 9.37 IL6 TNF
33 acute-phase response GO:0006953 9.33 HFE IL6 INS
34 glucose metabolic process GO:0006006 9.26 ADIPOQ INS LEP TNF
35 negative regulation of lipid storage GO:0010888 8.8 IL6 LEP TNF

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....